Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development

Acheson, Dean T.; Twamley, Elizabeth W.; Young, Jared W.

doi:10.3389/fnins.2013.00103

Cited by 26Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorNicotinic Acetylcholine Receptors Study

Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development

Open access

Acheson, Dean T., Twamley, Elizabeth W., Young, Jared W.·2013·Frontiers in Neuroscience

DOI 10.3389/fnins.2013.00103PMC PMC3684768

Open this paper in CoChat — free account Open PDF

Abstract

RATIONALE: Impaired cognitive abilities are a key characteristic of schizophrenia. Although currently approved pharmacological treatments have demonstrated efficacy for positive symptoms, to date no pharmacological treatments successfully reverse cognitive dysfunction in these patients. Cognitively-based interventions such as cognitive remediation (CR) and other psychosocial interventions however, may improve some of the cognitive and functional deficits of schizophrenia. Given that these treatments are time-consuming and labor-intensive, maximizing their effectiveness is a priority. Augmenting psychosocial interventions with pharmacological treatments may be a viable strategy for reducing the impact of cognitive deficits in patients with schizophrenia. OBJECTIVE: We propose a strategy to develop pharmacological treatments that can enhance the reward-related learning processes underlying successful skill-learning in psychosocial interventions. Specifically, we review clinical and preclinical evidence and paradigms that can be utilized to develop these pharmacological augmentation strategies. Prototypes for this approach include dopamine D1 receptor and α7 nicotinic acetylcholine receptor agonists as attractive targets to specifically enhance reward-related learning during CR. CONCLUSION: The approach outlined here could be used broadly to develop pharmacological augmentation strategies across a number of cognitive domains underlying successful psychosocial treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3389/fnins.2013.00103

Cites

162 of 162 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

No interventions yet target subclinical anhedonia or reinforcement-learning deficits in at-risk groups, but evidence suggests they could work.
“To our knowledge, interventions meant to target subclinical anhedonia or impairments in reinforcement learning in at risk populations have yet to be tested, however there is evidence for potential efficacy.”
From The effects of early life stress on reward processing (2018) · cites this paper as Acheson et al., 2013

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090 · see citing works
Chapter 12: What does the Anthropocene hold for citizenship?
(2019) · edoc (University of Basel) · doi:10.1007/978-3 · Cited by 11,533 · see citing works
Untitled work
Colman (2022) · doi:10.1073/pnas · Cited by 4,370 · see citing works
The American Journal of Psychiatry
(2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp · Cited by 2,611 · see citing works
Getting formal with dopamine and reward
Schultz, W. (2002) · Neuron · doi:10.1016/s0896-6273(02)00967-4 · Cited by 2,574 · see citing works
Model-based influences on humans’ choices and striatal prediction errors
Daw, N. D., Gershman, S. J., Seymour, B., Dayan, P., & Dolan, R. J. (2011) · Neuron · doi:10.1016/j.neuron.2011.02.027 · Cited by 1,779 · see citing works
A Meta-Analysis of Cognitive Remediation for Schizophrenia: Methodology and Effect Sizes
Wykes, T., Huddy, V., Cellard, C., McGurk, S. R., & Czobor, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10060855 · Cited by 1,693 · see citing works
Neuregulin 1 and Susceptibility to Schizophrenia
Stefánsson, H., Pétursson, H., Sigurðsson, E., Steinthórsdóttir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, S., Brynjolfsson, J., Gunnarsdottir, S., Ivarsson, O., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342734 · Cited by 1,671 · see citing works
Adaptive Coding of Reward Value by Dopamine Neurons
Tobler, P. N., Fiorillo, C. D., & Schultz, W. (2005) · Science · doi:10.1126/science.1105370 · Cited by 1,276 · see citing works
A Meta-Analysis of Cognitive Remediation in Schizophrenia
McGurk, S. R., Twamley, E. W., Sitzer, D. I., McHugo, G. J., & Mueser, K. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07060906 · Cited by 1,214 · see citing works
Self-citation
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141 · see citing works
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,072 · see citing works
. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor.
Wykes, T., Steel, C., Everitt, B., & Tarrier, N. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm114 · Cited by 1,029 · see citing works
Understanding dopamine and reinforcement learning: the dopamine reward prediction error hypothesis
Glimcher, P. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014269108 · Cited by 955 · see citing works
Modafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713 · see citing works
Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment
Harvey, P. D., & Keefe, R. S. E. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.176 · Cited by 617 · see citing works
The hippocampus and memory for orderly stimulus relations
Dusek, J. A., & Eichenbaum, H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.7109 · Cited by 610 · see citing works
Dysfunction of ventral striatal reward prediction in schizophrenia
Juckel, G., Schlagenhauf, F., Koslowski, M., Wüstenberg, T., Villringer, A., Knutson, B., Wrase, J., & Heinz, A. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2005.07.051 · Cited by 578 · see citing works
Neurochemical Modulation of Response Inhibition and Probabilistic Learning in Humans
Chamberlain, S. R., Müller, U., Blackwell, A. D., Clark, L., Robbins, T. W., & Sahakian, B. J. (2006) · Science · doi:10.1126/science.1121218 · Cited by 573 · see citing works
Association of Neuregulin 1 with Schizophrenia Confirmed in a Scottish Population
Stefánsson, H., Sarginson, J. E., Kong, A., Yates, P., Steinthórsdóttir, V., Gudfinnsson, E., Gunnarsdottir, S., Walker, N. P., Pétursson, H., Crombie, C., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/345442 · Cited by 555 · see citing works
Representation of negative motivational value in the primate lateral habenula
Matsumoto, M., & Hikosaka, O. (2009) · Nature Neuroscience · doi:10.1038/nn.2233 · Cited by 547 · see citing works
Neurocognitive Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol in Patients With Chronic Schizophrenia or Schizoaffective Disorder
Bilder, R. M., GOLDMAN, R. S., Volavka, J., Czobor, P., Hoptman, M. J., Sheitman, B., Lindenmayer, J., Citrome, L., McEvoy, J. P., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538 · see citing works
Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia
D, A. O. M., Harris, J. G., Johnson, L. L., Pender, V., Kongs, S., Allensworth, D., Ellis, J., Zerbe, G. O., Leonard, S. S., Stevens, K. E., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.630 · Cited by 531 · see citing works
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510 · see citing works
Expected value and prediction error abnormalities in depression and schizophrenia
Gradin, V. B., Kumar, P., Waiter, G., Ahearn, T., Stickle, C., Milders, M., Reid, I., Hall, J., & Steele, J. D. (2011) · Brain · doi:10.1093/brain/awr059 · Cited by 485 · see citing works
A system for relational reasoning in human prefrontal cortex
Waltz, J. A., Knowlton, B. J., Holyoak, K. J., Boone, K. B., Mishkin, F. S., de Menezes Santos, M., Thomas, C. R., & Miller, B. L. (1999) · Psychological Science · doi:10.1111/1467-9280.00118 · Cited by 472 · see citing works
Nicotine use in schizophrenia: The self medication hypotheses
Kumari, V., & Postma, P. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.02.006 · Cited by 470 · see citing works
Neuregulin 1 and Schizophrenia: Genetics, Gene Expression, and Neurobiology
Harrison, P. J., & Law, A. J. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.002 · Cited by 453 · see citing works
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.
Shen, W., Plotkin, J. L., Francardo, V., Ko, W. K. D., Xie, Z., Li, Q., Fieblinger, T., Wess, J., Neubig, R. R., Lindsley, C. W., et al. (2015) · HAL · doi:10.1016/j.neuron · Cited by 452 · see citing works
Social cognitive training for schizophrenia: a meta-analytic investigation of controlled research
Kurtz, M. M., & Richardson, C. L. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr036 · Cited by 446 · see citing works
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia
Buchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi020 · Cited by 438 · see citing works
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426 · see citing works
A Meta-Analysis of Controlled Research on Social Skills Training for Schizophrenia
Kurtz, M. M., & Mueser, K. T. (2008) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.76.3.491 · Cited by 425 · see citing works
Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia
Marder, S. R., & Fenton, W. S. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.010 · Cited by 419 · see citing works
Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5′ SNPs associated with the disease
Law, A. J., Lipska, B. K., Weickert, C. S., Hyde, T. M., Straub, R. E., Hashimoto, R., Harrison, P. J., Kleinman, J. E., & Weinberger, D. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602002103 · Cited by 403 · see citing works
Cognitive and behavioral treatments for anxiety disorders: A review of meta‐analytic findings
Deacon, B. J., & Abramowitz, J. S. (2004) · Journal of Clinical Psychology · doi:10.1002/jclp.10255 · Cited by 400 · cited 1× · see citing works
“Exposure-based treatments are effective in treating a wide range of trauma and anxiety-related disorders, including obsessivecompulsive disorder, panic disorder, social phobia, and posttraumatic stress disorder (Deacon and Abramowitz, 2004).”
Background
Efficacy of Psychological Therapy in Schizophrenia: Conclusions From Meta-analyses
Pfammatter, M. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl030 · Cited by 398 · see citing works
Nicotinic receptor subtypes and cognitive function
Levin, E. D. (2002) · Journal of Neurobiology · doi:10.1002/neu.10151 · Cited by 354 · see citing works
Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia
Martin, L., Kem, W., & Freedman, R. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1750-1 · Cited by 340 · see citing works
Transdermal nicotine effects on attention
Levin, E. D., Conners, C. K., Silva, D., Hinton, S. C., Meck, W. H., March, J. S., & Rose, J. E. (1998) · Psychopharmacology · doi:10.1007/s002130050750 · Cited by 331 · see citing works
A Review of Cognitive Training in Schizophrenia
Twamley, E. W., Jeste, D. V., & Bellack, A. S. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007011 · Cited by 329 · see citing works
Self-citation
Selective Reinforcement Learning Deficits in Schizophrenia Support Predictions from Computational Models of Striatal-Cortical Dysfunction
Waltz, J. A., Frank, M. J., Robinson, B. M., & Gold, J. M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.042 · Cited by 326 · see citing works
Serotonin Modulates Sensitivity to Reward and Negative Feedback in a Probabilistic Reversal Learning Task in Rats
Bari, A., Theobald, D. E., Caprioli, D., Mar, A. C., Aidoo-Micah, A., Dalley, J. W., & Robbins, T. W. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.233 · Cited by 325 · see citing works
Genetic Variation in CACNA1C Affects Brain Circuitries Related to Mental Illness
Bigos, K. L., Mattay, V. S., Callicott, J. H., Straub, R. E., Vakkalanka, R., Kolachana, B. S., Hyde, T. M., Lipska, B. K., Kleinman, J. E., & Weinberger, D. R. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.96 · Cited by 317 · see citing works
Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia
Young, J. W., Powell, S. B., Risbrough, V. B., Marston, H. M., & Geyer, M. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.02.004 · Cited by 299 · see citing works
Self-citation
α7 Nicotinic Receptor Subunits Are Not Necessary for Hippocampal-Dependent Learning or Sensorimotor Gating: A Behavioral Characterization of Acra7-Deficient Mice
Paylor, R., Nguyen, M., Crawley, J. N., Patrick, J., Beaudet, A., & Orr-Urtreger, A. (1998) · Learning & Memory · doi:10.1101/lm.5.4.302 · Cited by 298 · see citing works
Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.
Carter, C., & Barch, D. (2007) · Schizophrenia bulletin · doi:10.1093/schbul/sbm081 · Cited by 296 · see citing works
Psychomotor stimulants and neuronal plasticity
Wolf, M. E., Sun, X., Mangiavacchi, S., & Chao, S. Z. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.006 · Cited by 288 · see citing works
Fear extinction and BDNF: translating animal models of PTSD to the clinic
Andero, R., & Ressler, K. J. (2012) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2012.00801.x · Cited by 275 · see citing works
Midbrain dopaminergic neurons and striatal cholinergic interneurons encode the difference between reward and aversive events at different epochs of probabilistic classical conditioning trials
Joshua, M., Adler, A., Mitelman, R., Vaadia, E., & Bergman, H. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3839-08.2008 · Cited by 273 · see citing works
Psychosocial Treatments to Promote Functional Recovery in Schizophrenia
Kern, R. S., Glynn, S. M., Horan, W. P., & Marder, S. R. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn177 · Cited by 267 · see citing works
Integrated Psychological Therapy (IPT) for Schizophrenia: Is It Effective?
Roder, V. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl021 · Cited by 260 · see citing works
The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine
Weiner, D. M., Meltzer, H. Y., Veinbergs, I., Donohue, E. M., Spalding, T. A., Smith, T. T., Mohell, N., Harvey, S. C., Lameh, J., Nash, N. T., et al. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1940-5 · Cited by 253 · see citing works
Efficacy of D-Cycloserine for Enhancing Response to Cognitive-Behavior Therapy for Panic Disorder
Otto, M. W., Tolin, D. F., Simon, N. M., Pearlson, G. D., Basden, S., Meunier, S. A., Hofmann, S. G., Eisenmenger, K., Krystal, J. H., & Pollack, M. H. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.07.036 · Cited by 251 · see citing works
D1 but not D5 Dopamine Receptors Are Critical for LTP, Spatial Learning, and LTP-Induced arc and zif268 Expression in the Hippocampus
Granado, N., Ortiz, Ó., Suárez, L. M., Martín, E. D., Ceña, V., Solís, J. M., & Moratalla, R. (2007) · Cerebral Cortex · doi:10.1093/cercor/bhm026 · Cited by 249 · see citing works
Is Serum Brain-Derived Neurotrophic Factor a Biomarker for Cognitive Enhancement in Schizophrenia?
Vinogradov, S., Fisher, M., Holland, C. M., Shelly, W. B., Wolkowitz, O. M., & Mellon, S. H. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.02.017 · Cited by 241 · see citing works
The Effects of Transdermal Nicotine on Cognition in Nonsmokers with Schizophrenia and Nonpsychiatric Controls
Barr, R. S., Maravić, M. C., Jubelt, L. E., Mufti, R. S., Dyer, M. A., Weiss, A. P., Deckersbach, T., Kelly, J. F., Freudenreich, O., GOFF, D. C., et al. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301423 · Cited by 238 · see citing works
Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice
Young, J. W., Crawford, N., Kelly, J. S., Kerr, L. E., Marston, H. M., Spratt, C., Finlayson, K., & Sharkey, J. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.03.008 · Cited by 233 · see citing works
Self-citation
Deficits in Positive Reinforcement Learning and Uncertainty-Driven Exploration Are Associated with Distinct Aspects of Negative Symptoms in Schizophrenia
Strauss, G. P., Frank, M. J., Waltz, J. A., Kasanova, Z., Herbener, E. S., & Gold, J. M. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.10.015 · Cited by 232 · see citing works
Dopaminergic D1and D2Receptors Are Essential for the Arousal Effect of Modafinil
Qu, W., Huang, Z., Xu, X., Matsumoto, N., & Urade, Y. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.1819-08.2008 · Cited by 230 · see citing works
Neuroplasticity-Based Cognitive Training in Schizophrenia: An Interim Report on the Effects 6 Months Later
Fisher, M., Holland, C. M., Subramaniam, K., & Vinogradov, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn170 · Cited by 221 · see citing works
A Randomized Placebo-Controlled Trial of d-Cycloserine to Enhance Exposure Therapy for Posttraumatic Stress Disorder
de Kleine, R. A., Hendriks, G.-J., Kusters, W. J. C., Broekman, T. G., & van Minnen, A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.033 · Cited by 220 · see citing works
The Cognitive Cost of Anticholinergic Burden: Decreased Response to Cognitive Training in Schizophrenia
Vinogradov, S., Fisher, M., Warm, H., Holland, C. M., Kirshner, M. A., & Pollock, B. G. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09010017 · Cited by 220 · see citing works
Nicotine Improves Sustained Attention in Mice: Evidence for Involvement of the α7 Nicotinic Acetylcholine Receptor
Young, J. W., Finlayson, K., Spratt, C., Marston, H. M., Crawford, N., Kelly, J. S., & Sharkey, J. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300393 · Cited by 219 · see citing works
Self-citation
Initiatives to Promote the Discovery of Drugs to Improve Cognitive Function in Severe Mental Illness
Marder, S. R. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0706e03 · Cited by 218 · see citing works
Hippocampal α7 and α4β2 nicotinic receptors and working memory
Levin, E. D., Bradley, A., Addy, N., & Sigurani, N. (2002) · Neuroscience · doi:10.1016/s0306-4522(01)00538-3 · Cited by 202 · see citing works
Compensatory Cognitive Training for Psychosis
Twamley, E. W., Vella, L., Burton, C. Z., Heaton, R. K., & Jeste, D. V. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07686 · Cited by 200 · see citing works
Self-citation
The Neurobiology of Cognition in Schizophrenia
Tamminga, C. A. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0906e11 · Cited by 198 · see citing works
Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21
Arendash, G. W., Sengstock, G. J., Sanberg, P. R., & Kem, W. R. (1995) · Brain Research · doi:10.1016/0006-8993(94)01449-r · Cited by 198 · see citing works
Deletion of the 7 Nicotinic Acetylcholine Receptor Gene Improves Cognitive Deficits and Synaptic Pathology in a Mouse Model of Alzheimer's Disease
Dziewczapolski, G., Głogowski, M., Masliah, E., & Heinemann, S. F. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.6159-08.2009 · Cited by 197 · see citing works
Differences in BTBR T+ tf/J and C57BL/6J mice on probabilistic reversal learning and stereotyped behaviors
Amodeo, D. A., Jones, J. H., Sweeney, J. A., & Ragozzino, M. E. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.10.032 · Cited by 191 · see citing works
Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection
Surmeier, D. J., Plotkin, J. L., & Shen, W. (2009) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2009.10.003 · Cited by 183 · see citing works
A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia
Lieberman, J. A., Dunbar, G. C., Segreti, A. C., Girgis, R. R., Seoane, F., Beaver, J. S., Duan, N., & Hosford, D. A. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.259 · Cited by 176 · see citing works
Dynamic Gain Control of Dopamine Delivery in Freely Moving Animals
Montague, P. R., McClure, S. M., Baldwin, P. R., Phillips, P. E. M., Budygin, E. A., Stuber, G. D., Kilpatrick, M., & Wightman, R. M. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.4279-03.2004 · Cited by 174 · see citing works
Galantamine for the treatment of cognitive impairments in people with schizophrenia
Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M., & McMahon, R. P. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050724 · Cited by 170 · see citing works
Psychotherapy plus antidepressant for panic disorder with or without agoraphobia
Furukawa, T. A., Watanabe, N., & Churchill, R. C. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.188.4.305 · Cited by 165 · see citing works
Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease
Potter, A., Corwin, J., Lang, J., Piasecki, M., Lenox, R., & Newhouse, P. A. (1999) · Psychopharmacology · doi:10.1007/s002130050897 · Cited by 163 · see citing works
A Randomized, Controlled Trial of Computer-Assisted Cognitive Remediation for Schizophrenia
Dickinson, D., Tenhula, W. N., Morris, S. E., Brown, C., Peer, J. E., Spencer, K., Li, L., Gold, J. M., & Bellack, A. S. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020264 · Cited by 157 · see citing works
Dysfunctional long-term potentiation-like plasticity in schizophrenia revealed by transcranial direct current stimulation
Hasan, A., Nitsche, M. A., Rein, B., Schneider-Axmann, T., Guse, B., Gruber, O., Falkai, P., & Wobrock, T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.05.017 · Cited by 156 · see citing works
Computer-assisted cognitive remediation in schizophrenia: What is the active ingredient?
Kurtz, M. M., Seltzer, J. C., Shagan, D. S., Thime, W., & Wexler, B. E. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.09.001 · Cited by 155 · see citing works
Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: clinical implications for exposure therapy*
Davis, M. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02138.x · Cited by 154 · see citing works
Acute nicotinic blockade produces cognitive impairment in normal humans
NEWHOUSE, P. A., Potter, A., Corwin, J., & Lenox, R. H. (1992) · Psychopharmacology · doi:10.1007/bf02247425 · Cited by 149 · see citing works
Long-term potentiation: Peeling the onion
Nicoll, R. A., & Roche, K. W. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.02.010 · Cited by 146 · see citing works
Associative Learning and CA3–CA1 Synaptic Plasticity Are Impaired in D1R Null,Drd1a−/−Mice and in Hippocampal siRNA SilencedDrd1aMice
Ortiz, O., Delgado-García, J. M., Espadas, I., Bahí, A., Trullas, R., Dreyer, J.-L., Gruart, A., & Moratalla, R. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2655-10.2010 · Cited by 143 · see citing works
Dose-Related Enhancement of Mood and Cognition in Smokers Administered Nicotine Nasal Spray
Myers, C. S., Taylor, R. C., Moolchan, E. T., & Heishman, S. J. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301425 · Cited by 143 · see citing works
The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample
Acheson, D., Feifel, D., de Wilde, S., Mckinney, R., Lohr, J., & Risbrough, V. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3099-4 · Cited by 141 · see citing works
Self-citation
Transitive inference in schizophrenia: impairments in relational memory organization
Titone, D. A. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00152-x · Cited by 139 · see citing works
Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?
Keefe, R. S. E., Buchanan, R. W., Marder, S. R., Schooler, N. R., Dugar, A., Zivkov, M., & Stewart, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr153 · Cited by 138 · see citing works
Subunit specificity and mechanism of action of NMDA partial agonist d-cycloserine
Sheinin, A., Shavit, S., & Benveniste, M. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00073-9 · Cited by 136 · see citing works
Enhancing exposure therapy for anxiety disorders with glucocorticoids: From basic mechanisms of emotional learning to clinical applications
Bentz, D., Michael, T., de Quervain, D. J. ‐., & Wilhelm, F. H. (2009) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2009.10.011 · Cited by 136 · see citing works
Altered probabilistic learning and response biases in schizophrenia: Behavioral evidence and neurocomputational modeling.
Waltz, J. A., Frank, M. J., Wiecki, T. V., & Gold, J. M. (2011) · Neuropsychology · doi:10.1037/a0020882 · Cited by 132 · see citing works
Chronic nicotine and withdrawal effects on radial-arm maze performance in rats
Levin, E. D., Lee, C. K., Rose, J. E., Reyes, A., Ellison, G. D., Jarvik, M. E., & Gritz, E. R. (1990) · Behavioral and Neural Biology · doi:10.1016/0163-1047(90)90509-5 · Cited by 130 · see citing works
Adjunctive psychosocial therapies for the treatment of schizophrenia
Patterson, T. L., & Leeuwenkamp, O. R. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.468 · Cited by 126 · see citing works
Nicotinic α7- or β2-containing receptor knockout: Effects on radial-arm maze learning and long-term nicotine consumption in mice
Levin, E. D., Petro, A. E., Rezvani, A. H., Pollard, N., Christopher, N. C., Strauss, M., Avery, J., Nicholson, J. L., & Rose, J. E. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.08.048 · Cited by 123 · see citing works
Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits
D’Souza, M. S., & Markou, A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.044 · Cited by 121 · see citing works
Animal models of working memory: A review of tasks that might be used in screening drug treatments for the memory impairments found in schizophrenia
Dudchenko, P. A., Talpos, J. C., Young, J. W., & Baxter, M. G. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.03.003 · Cited by 120 · see citing works
Self-citation
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia
Javitt, D. C., Buchanan, R. W., Keefe, R. S. E., Kern, R. S., McMahon, R. P., Green, M. F., Lieberman, J. A., GOFF, D. C., Csernansky, J. G., McEvoy, J. P., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.001 · Cited by 118 · see citing works
CNTRICS final animal model task selection: Control of attention
Lustig, C., Kozak, R., Sarter, M. F., Young, J. W., & Robbins, T. W. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.05.009 · Cited by 117 · see citing works
Self-citation
Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits
Poltavski, D., & Petros, T. V. (2006) · Physiology & Behavior · doi:10.1016/j.physbeh.2005.12.011 · Cited by 110 · see citing works
Predicting Drug Efficacy for Cognitive Deficits in Schizophrenia
Hagan, J. J. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi058 · Cited by 109 · see citing works
Dopamine D1-deficient mutant mice do not express the late phase of hippocampal long-term potentiation
Matthies, H., Becker, A., Schröeder, H., Kraus, J., Höllt, V., & Krug, M. (1997) · Neuroreport · doi:10.1097/00001756-199711100-00023 · Cited by 106 · see citing works
Nicotine and Nicotinic Receptor Involvement in Neuropsychiatric Disorders
NEWHOUSE, P. A., Singh, A., & Potter, A. S. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043451401 · Cited by 106 · see citing works
A Selective Review of Volumetric and Morphometric Imaging in Schizophrenia
Levitt, J. J., Bobrow, L., Lucia, D., & Srinivasan, P. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_53 · Cited by 104 · see citing works
Social Bonding Decreases the Rewarding Properties of Amphetamine through a Dopamine D1 Receptor-Mediated Mechanism
Liu, Y., Young, K. A., Curtis, J. T., Aragona, B. J., & Wang, Z. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1006-11.2011 · Cited by 103 · see citing works
Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia
Martin-Ruiz, C. M., Haroutunian, V. H., Long, P., Young, A. H., Davis, K. L., Perry, E. K., & Court, J. A. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00348-2 · Cited by 100 · see citing works
Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats.
Rezvani, A., Kholdebarin, E., Brucato, F., Callahan, P., Lowe, D., & Levin, E. (2009) · Progress in Neuro-psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.11.018 · Cited by 97 · see citing works
Animal Models of Schizophrenia
Young, J. W., Zhou, X., & Geyer, M. A. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_62 · Cited by 96 · see citing works
Self-citation
Developing Predictive Animal Models and Establishing a Preclinical Trials Network for Assessing Treatment Effects on Cognition in Schizophrenia
Floresco, S. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi041 · Cited by 95 · see citing works
ECNP Summit on the future of CNS drug research in Europe 2011: Report prepared for ECNP by David Nutt and Guy Goodwin
Nutt, D., & Goodwin, G. M. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.05.004 · Cited by 94 · see citing works
Delayed procedural learning in α7-nicotinic acetylcholine receptor knockout mice
Young, J. W., Meves, J. M., Tarantino, I. S., Caldwell, S., & Geyer, M. A. (2011) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2011.00711.x · Cited by 93 · see citing works
Self-citation
Nicotine enhances the learning and memory of aged rats
Aren-, G. W., Sanberg, P. R., & Sengstock, G. J. (1995) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)00119-h · Cited by 90 · see citing works
Attention Shaping: a Reward-Based Learning Method to Enhance Skills Training Outcomes in Schizophrenia
Silverstein, S. M., Spaulding, W. D., Menditto, A. A., Savitz, A. J., Liberman, R. P., Berten, S., & Starobin, H. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm150 · Cited by 89 · see citing works
Genetic Neuropathology of Schizophrenia: New Approaches to an Old Question and New Uses for Postmortem Human Brains
Kleinman, J. E., Law, A. J., Lipska, B. K., Hyde, T. M., Ellis, J. K., Harrison, P. J., & Weinberger, D. R. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.10.032 · Cited by 88 · see citing works
Combined pharmacotherapy and cognitive-behavioral therapy for anxiety disorders: medication effects, glucocorticoids, and attenuated treatment outcomes.
Otto, M. W., McHugh, R. K., & Kantak, K. M. (2010) · Clinical Psychology Science and Practice · doi:10.1111/j.1468-2850.2010.01198.x · Cited by 87 · see citing works
A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia
Mu, Q., Johnson, K. A., Morgan, P. S., Grenesko, E. L., Molnar, C., Anderson, B. S., Nahas, Z. H., Kozel, F. A., Köse, S., Knable, M. B., et al. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.033 · Cited by 85 · see citing works
A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia
George, M. S., Molnar, C., Grenesko, E. L., Anderson, B. S., Mu, Q., Johnson, K. A., Nahas, Z. H., Knable, M. B., FERNANDES, P. B., Juncos, J. L., et al. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.011 · Cited by 84 · see citing works
Dopamine neurons learn to encode the long-term value of multiple future rewards
Enomoto, K., Matsumoto, N., Nakai, S., Satoh, T., Sato, T. K., Ueda, Y., Inokawa, H., Haruno, M., & Kimura, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014457108 · Cited by 83 · see citing works
Report From the Working Group Conference on Multisite Trial Design for Cognitive Remediation in Schizophrenia
Keefe, R. S. E., Vinogradov, S., Medalia, A. A., Silverstein, S. M., Bell, M. D., Dickinson, D., Ventura, J., Marder, S. R., & Stroup, T. S. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq010 · Cited by 83 · see citing works
Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain.
Scoriels, L., Jones, P., & Sahakian, B. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.011 · Cited by 83 · see citing works
Action of Modafinil—Increased Motivation Via the Dopamine Transporter Inhibition and D1 Receptors?
Young, J. W., & Geyer, M. A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.12.015 · Cited by 82 · see citing works
Self-citation
Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease.
Blanchet, P. J., Fang, J., Gillespie, M., et al. (1999) · PubMed · Cited by 80 · see citing works
Are we studying and treating schizophrenia correctly?
Swerdlow, N. R. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.05.004 · Cited by 77 · see citing works
Prefrontal cortex: Role in acquisition of overlapping associations and transitive inferencePreprint
DeVito, L. M., Lykken, C. M., Kanter, B. R., & Eichenbaum, H. (2010) · Learning & Memory · doi:10.1101/lm.1685710 · Cited by 75 · see citing works
Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia
Dolan, S. L. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.01.006 · Cited by 69 · see citing works
Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test
Young, J. W., Meves, J. M., & Geyer, M. A. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.11.028 · Cited by 69 · see citing works
Self-citation
Reversal of a Vigilance Decrement in the Aged Rat by Subtype-Selective Nicotinic Ligands
Grottick, A. J., Haman, M., Wyler, R., & Higgins, G. A. (2002) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300102 · Cited by 68 · see citing works
Enviromimetics: exploring gene environment interactions to identify therapeutic targets for brain disorders
McOmish, C. E., & Hannan, A. J. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.7.899 · Cited by 65 · see citing works
Subtype-selective nicotinic agonists enhance olfactory working memory in normal rats: A novel use of the odour span task
Rushforth, S. L., Allison, C., Wonnacott, S., & Shoaib, M. C. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.01.022 · Cited by 65 · see citing works
The odour span task: A novel paradigm for assessing working memory in mice
Young, J. W., Kerr, L. E., Kelly, J. S., et al. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.09.006 · Cited by 64 · see citing works
Self-citation
The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia
Weiss, E. M., Bilder, R. M., & Fleischhacker, W. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1053-y · Cited by 63 · see citing works
α7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1
Mathew, S., Law, A. J., Lipska, B. K., Dávila‐García, M. I., Zamora, E. D., Mitkus, S. N., Vakkalanka, R., Straub, R. E., Weinberger, D. R., Kleinman, J. E., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm253 · Cited by 63 · see citing works
The partial α7 nicotine acetylcholine receptor agonist S 24795 enhances long-term potentiation at CA3-CA1 synapses in the adult mouse hippocampus
Lagostena, L., Trocmé, C., Morain, P., & Cherubini, E. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.11.016 · Cited by 59 · see citing works
Selective nicotinic receptor antagonists: effects on attention and nicotine-induced attentional enhancement
Hahn, B., Shoaib, M. C., & Stolerman, I. P. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2258-8 · Cited by 59 · see citing works
Performance of α7 nicotinic receptor null mutants is impaired in appetitive learning measured in a signaled nose poke task
Keller, J. J., Keller, A. B., Bowers, B. J., & Wehner, J. M. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.03.004 · Cited by 57 · see citing works
CNTRICS Final Task Selection: Long-Term Memory
Ragland, J. D., Cools, R., Frank, M. J., Pizzagalli, D. A., Preston, A. R., Charan Ranganath, A., & Wagner, A. D. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn134 · Cited by 57 · see citing works
Impairment of probabilistic reward-based learning in schizophrenia.
Weiler, J. A., Bellebaum, C., Brüne, M., Juckel, G., & Daum, I. (2009) · Neuropsychology · doi:10.1037/a0016166 · Cited by 55 · see citing works
Effect of d-cycloserine and valproic acid on the extinction of reinstated fear-conditioned responses and habituation of fear conditioning in healthy humans: a randomized controlled trial
Kuriyama, K., Honma, M., Soshi, T., Fujii, T., & Kim, Y. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2353-x · Cited by 54 · see citing works
CNTRICS Final Biomarker Selection: Control of Attention
Luck, S. J., Ford, J. M., Sarter, M. F., & Lustig, C. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr065 · Cited by 48 · see citing works
Cognitive Improvement in Response to Antipsychotic Drugs
Heinrichs, R. W. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.631 · Cited by 46 · see citing works
Applying New Approaches From Cognitive Neuroscience to Enhance Drug Development for the Treatment of Impaired Cognition in Schizophrenia
Carter, C. S. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi046 · Cited by 46 · see citing works
Drug initiatives to improve cognitive function.
Marder, S. R. (2006) · PubMed · Cited by 43 · see citing works
Consideration of species differences in developing novel molecules as cognition enhancers
Young, J. W., Jentsch, J. D., Bussey, T. J., Wallace, T. L., & Hutcheson, D. M. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.10.002 · Cited by 42 · see citing works
Self-citation
Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia
Bencherif, M., Stachowiak, M. K., Kucinski, A. J., & Lippiello, P. M. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.01.035 · Cited by 37 · see citing works
Nicotinic-antipsychotic drug interactions and cognitive function
Levin, E. D., & Rezvani, A. H. (2006) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-7772-4_10 · Cited by 36 · see citing works
Cost‐effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain
Gutiérrez-Recacha, P., Chisholm, D., Haro, J. M., Salvador‐Carulla, L., & Ayuso‐Mateos, J. L. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00917.x · Cited by 36 · see citing works
Neuroplasticity as a Target for the Pharmacotherapy of Psychiatric Disorders: New Opportunities for Synergy with Psychotherapy
Krystal, J. H. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.017 · Cited by 34 · see citing works
Mouse pharmacological models of cognitive disruption relevant to schizophrenia
Young, J. W., Powell, S. B., & Geyer, M. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.06.013 · Cited by 32 · see citing works
Self-citation
Striatal action-learning based on dopamine concentration
Morris, G., Schmidt, R., & Bergman, H. (2009) · Experimental Brain Research · doi:10.1007/s00221-009-2060-6 · Cited by 32 · see citing works
Differential effects of subtype-specific nicotinic acetylcholine receptor agonists on early and late hippocampal LTP
Kroker, K. S., Rast, G. F., & Rosenbrock, H. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.09.167 · Cited by 31 · see citing works
CUtLASS Confirms CATIE
Mintz, J., & Kopelowicz, A. J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.8.978-a · Cited by 30 · see citing works
Dopamine D1and D2Receptor Family Contributions to Modafinil-Induced Wakefulness
Young, J. W. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.5843-08.2009 · Cited by 27 · see citing works
Self-citation
Behavioral Animal Models to Assess Pro-cognitive Treatments for Schizophrenia
Young, J. W., Amitai, N., & Geyer, M. A. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_3 · Cited by 26 · see citing works
Self-citation
Towards Medication-Enhancement of Cognitive Interventions in Schizophrenia
Chou, H., Twamley, E. W., & Swerdlow, N. R. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_4 · Cited by 23 · see citing works
Self-citation
Distinct Neural Pathways Mediate α7 Nicotinic Acetylcholine Receptor–Dependent Activation of the Forebrain
Thomsen, M. S., Hay‐Schmidt, A., Hansen, H. H., & Mikkelsen, J. D. (2010) · Cerebral Cortex · doi:10.1093/cercor/bhp283 · Cited by 23 · see citing works
Molecular Neuro Anatomic Mechanisms of Parkinson’s Disease: A Proposed Therapeutic Approach
Gerfen, C. R., & Engber, T. M. (1992) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30220-2 · Cited by 22 · see citing works
The potential of nicotinic enhancement of cognitive remediation training in schizophrenia
Hahn, B., Gold, J. M., & Buchanan, R. W. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.050 · Cited by 18 · see citing works
Comparison of the enantiomers of (±)-doxanthrine, a high efficacy full dopamine D1 receptor agonist, and a reversal of enantioselectivity at D1 versus alpha2C adrenergic receptors
Przybyla, J. A., Cueva, J. P., Chemel, B. R., et al. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.10.002 · Cited by 15 · see citing works
Synthesis of 6-substituted 1-phenylbenzazepines and their dopamine D1 receptor activities
Zhang, J., Chen, X., Yu, L.-P., et al. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.09.049 · Cited by 14 · see citing works
Limits of learning enhancements with nicotine in old male rats
Taylor, G. T., Bassi, C. J., & Weiss, J. (2005) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2005-1545 · Cited by 13 · see citing works
Targeting Reward-Relevant Nicotinic Receptors in the Discovery of Novel Pharmacotherapeutic Agents to Treat Tobacco Dependence
Dwoskin, L. P., Pivavarchyk, M., Joyce, B. M., Neugebauer‎, N. M., Zheng, G., Zhang, Z., Bardo, M. T., & Crooks, P. A. (2008) · Nebraska Symposium on Motivation/The Nebraska symposium on motivation · doi:10.1007/978-0-387-78748-0_4 · Cited by 11 · see citing works
New Opportunities in the Treatment of Cognitive Impairments Associated With Schizophrenia
Geyer, M. A. (2010) · Current Directions in Psychological Science · doi:10.1177/0963721410378359 · Cited by 10 · see citing works
Comparison of the D1 dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease
McCorvy, J. D., Watts, V. J., & Nichols, D. E. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2625-5 · Cited by 7 · see citing works

Flagged first, then by citations

Sorted by citations

The effects of early life stress on reward processing
Novick, A. M., Levandowski, M. L., Laumann, L. E., Philip, N. S., Price, L. H., & Tyrka, A. R. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.02.002 · Cited by 192 · see citing works
“Given the role of dopamine in various aspects of reward processing, dopaminergic agents might have utility in enhancing reward learning and approach motivation when used in conjunction with behavioral training (Acheson et al., 2013; Admon et al., 2016).”
Background
Neural Circuitry of Salience and Reward Processing in Psychosis
Kesby, J. P., Murray, G. K., & Knolle, F. (2023) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2021.12.003 · Cited by 55 · see citing works

Authors: Acheson, D. T., Twamley, E. W., & Young, J. W.
Affiliations: University of California San Diego (US)
Corresponding author: Young, Jared W.
ORCID: Twamley, Elizabeth W.
Young, Jared W.
Venue: Frontiers in Neuroscience
Publisher: Frontiers Media SA
Published: 2013
Volume: 7
Pages: 103-103
ISSN: 1662-453X (ISSN-L)
DOI: 10.3389/fnins.2013.00103
PMC: PMC3684768
OpenAlex: W1991130665
Cited by: 26
References: 162
Citations by year: 2024: 1 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 7 · 2016: 1 · 2015: 3 · 2014: 2 · 2013: 1
FWCI: 1.66
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
Locations: Frontiers in Neuroscience (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
eScholarship (California Digital Library) (submittedVersion)
eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders: National Alliance for Research on Schizophrenia and Depression
National Institute of Mental Health (P30MH080002, MH091571, MH93453, MH080002, R34 MH93453, MH080150, R01MH080150, R21MH091571)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Keywords: schizophrenia, cognitive remediation, reward learning, drug augmentation, cognitive impairment, dopamine D1 receptor agonist, α7 nicotinic acetylcholine receptor agonist, psychosocial interventions, skill acquisition, preclinical drug development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks